FDA Inspection 1324478 — Octapharma USA, Inc.
The FDA completed an inspection of Octapharma USA, Inc. on Jun 25, 2026 in Paramus, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 25, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Paramus, NJ (United States)
Additional Details
Sponsor, Contract Research Organization